Reduced Immune Response to Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Cohort of Immunocompromised Patients in Chile

Simple item page
dc.catalogadoryvc
dc.contributor.authorBalcells Marty, María Elvira
dc.contributor.authorLe Corre Pérez, Monique Nicole
dc.contributor.authorDurán Santa Cruz, Josefina Gracia
dc.contributor.authorCeballos Valdivielso, María Elena Andrea
dc.contributor.authorVizcaya Altamirano, María Cecilia
dc.contributor.authorMondaca Contreras, Sebastián Patricio
dc.contributor.authorDib Marambio, Martin Javier
dc.contributor.authorRabagliati Borie, Ricardo Miguel
dc.contributor.authorSarmiento Maldonado, Mauricio
dc.contributor.authorBurgos Cañete, Paula Isabel
dc.contributor.authorEspinoza Sepúlveda, Manuel Antonio
dc.contributor.authorFerres Garrido, Marcela Viviana
dc.contributor.authorMartínez Valdebenito, Constanza Pamela
dc.contributor.authorRuiz-Tagle Seguel, Cinthya Grace
dc.contributor.authorOrtiz Koh, Catalina Alejandra
dc.contributor.authorRoss Pérez, Patricio Daniel
dc.contributor.authorBudnik Bitran, Sigall
dc.contributor.authorSolari Gajardo, Sandra
dc.contributor.authorVizcaya Vergara, María De Los Ángeles
dc.contributor.authorLembach, Hanns
dc.contributor.authorBerríos Rojas, Roslye
dc.contributor.authorMelo González, Felipe
dc.contributor.authorRios Raggio, Mariana
dc.contributor.authorKalergis Parra, Alexis Mikes
dc.contributor.authorBueno Ramírez, Susan Marcela
dc.contributor.authorNervi Nattero, Bruno
dc.date.accessioned2022-07-15T18:52:49Z
dc.date.available2022-07-15T18:52:49Z
dc.date.issued2022
dc.description.abstractBackground Inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have been widely implemented in low- and middle-income countries. However, immunogenicity in immunocompromised patients has not been established. Herein, we aimed to evaluate immune response to CoronaVac vaccine in these patients. Methods This prospective cohort study included 193 participants with 5 different immunocompromising conditions and 67 controls, receiving 2 doses of CoronaVac 8-12 weeks before enrollment. The study was conducted between May and August 2021, at Red de Salud UC-CHRISTUS, Santiago, Chile. Neutralizing antibody (NAb) positivity, total anti-SARS-CoV-2 immunoglobulin G antibody (TAb) concentrations, and T-cell responses were determined. Results NAb positivity and median neutralizing activity were 83.1% and 51.2% for the control group versus 20.6% and 5.7% (both P < .001) in the solid organ transplant group, 41.5% and 19.2% (both P < .0001) in the autoimmune rheumatic diseases group, 43.3% (P < .001) and 21.4% (PP = .001) in the cancer with solid tumors group, 45.5% and 28.7% (both P < .001) in the human immunodeficiency virus (HIV) infection group, 64.3% and 56.6% (both differences not significant) in the hematopoietic stem cell transplant group, respectively. TAb seropositivity was also lower for the solid organ transplant (20.6%; P < .0001), rheumatic diseases (61%; P < .001), and HIV groups (70.9%; P = .003), compared with the control group (92.3%). On the other hand, the number of interferon gamma spot-forming T cells specific for SARS-CoV-2 tended to be lower in all immunocompromising conditions but did not differ significantly between groups. Conclusions Diverse immunocompromising conditions markedly reduce the humoral response to CoronaVac vaccine. These findings suggest that a boosting vaccination strategy should be considered in these vulnerable patients.
dc.description.abstractWe assessed the immune response to a severe acute respiratory syndrome coronavirus-2 vaccine in immunocompromised patients. Humoral response in these patients was markedly reduced versus controls. We propose alternative vaccination schemes and/or the application of vaccine boosters in these patients..
dc.fechaingreso.objetodigital2023-11-06
dc.fuente.origenWOS
dc.identifier.doi10.1093/cid/ciac167
dc.identifier.eissn1537-6591
dc.identifier.issn1058-4838
dc.identifier.urihttps://doi.org/10.1093/cid/ciac167
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/75235
dc.identifier.wosidWOS:000796643900001
dc.information.autorucEscuela de Medicina; Balcells Marty, María Elvira; 0000-0002-7223-9665; 7462
dc.information.autorucFacultad de Ciencias Biológicas; Le Corre Pérez, Monique Nicole; 0000-0002-9361-4049; 6737
dc.information.autorucEscuela de Medicina; Durán Santa Cruz, Josefina Gracia; S/I; 159703
dc.information.autorucEscuela de Medicina; Ceballos Valdivielso, María Elena Andrea; 0000-0002-5569-6485; 190187
dc.information.autorucEscuela de Medicina; Vizcaya Altamirano, María Cecilia; 0000-0003-1309-9778; 7645
dc.information.autorucEscuela de Medicina; Mondaca Contreras, Sebastián Patricio; 0000-0002-1130-0370; 190152
dc.information.autorucEscuela de Medicina; Dib Marambio, Martin Javier;S/I; 1103640
dc.information.autorucEscuela de Medicina; Rabagliati Borie, Ricardo Miguel; S/I; 59169
dc.information.autorucEscuela de Medicina; Sarmiento Maldonado, Mauricio; 0000-0003-3715-9886; 167160
dc.information.autorucEscuela de Medicina; Burgos Cañete, Paula Isabel; 0000-0002-1526-0126; 93093
dc.information.autorucEscuela de Medicina; Espinoza Sepúlveda, Manuel Antonio; 0000-0001-9564-9512; 10720
dc.information.autorucEscuela de Medicina; Ferres Garrido, Marcela Viviana; 0000-0001-9415-4657; 66180
dc.information.autorucEscuela de Medicina; Martínez Valdebenito, Constanza Pamela; S/I; 1007539
dc.information.autorucEscuela de Medicina; Ruiz-Tagle Seguel, Cinthya Grace; S/I; 1098594
dc.information.autorucEscuela de Medicina; Ortiz Koh, Catalina Alejandra; S/I; 1094790
dc.information.autorucEscuela de Medicina; Ross Pérez, Patricio Daniel; S/I; 1095610
dc.information.autorucEscuela de Medicina; Budnik Bitran, Sigall; ; 214341
dc.information.autorucEscuela de Medicina; Solari Gajardo, Sandra; S/I; 1871
dc.information.autorucEscuela de Medicina; Vizcaya Vergara, María De Los Ángeles; S/I; 1089212
dc.information.autorucFacultad de Ciencias Biológicas; Rios Raggio, Mariana; S/I; 50388
dc.information.autorucFacultad de Ciencias Biológicas; Kalergis Parra, Alexis Mikes; 0000-0001-7622-5263; 90610
dc.information.autorucFacultad de Ciencias Biológicas; Bueno Ramírez, Susan Marcela; 0000-0002-7551-8088; 113541
dc.information.autorucEscuela de Medicina; Nervi Nattero, Bruno; 0000-0002-3016-7261; 604
dc.language.isoen
dc.nota.accesoContenido parcial
dc.publisherOxford University Press for the Infectious Diseases Society of America
dc.rightsacceso restringido
dc.subjectSARS-CoV-2
dc.subjectCOVID-19
dc.subjectCoronaVac
dc.subjectInactivated vaccine
dc.subjectImmunocompromised patient
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleReduced Immune Response to Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Cohort of Immunocompromised Patients in Chile
dc.typeartículo
sipa.codpersvinculados7462
sipa.codpersvinculados6737
sipa.codpersvinculados159703
sipa.codpersvinculados190187
sipa.codpersvinculados7645
sipa.codpersvinculados190152
sipa.codpersvinculados1103640
sipa.codpersvinculados59169
sipa.codpersvinculados167160
sipa.codpersvinculados93093
sipa.codpersvinculados10720
sipa.codpersvinculados66180
sipa.codpersvinculados1007539
sipa.codpersvinculados1098594
sipa.codpersvinculados1094790
sipa.codpersvinculados1095610
sipa.codpersvinculados214341
sipa.codpersvinculados1871
sipa.codpersvinculados1089212
sipa.codpersvinculados50388
sipa.codpersvinculados90610
sipa.codpersvinculados113541
sipa.codpersvinculados604
sipa.indexWOS
sipa.trazabilidadWOS;2022-07-08
sipa.trazabilidadORCID;2023-10-30
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
RESUMEN_Reduced Immune Response to Inactivated Severe.pdf
Size:
114.13 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas